<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nid</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология и диализ</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology and Dialysis</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1680-4422</issn><issn pub-type="epub">2618-9801</issn><publisher><publisher-name>Российское диализное общество</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">nid-3781</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Оптимизация иммуносупрессивного лечения после аллотрансплантации почки</article-title><trans-title-group xml:lang="en"><trans-title>Improvement Of Immunisupressive Therapie After Kidney Allotransplantation</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калачик</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalatchik</surname><given-names>O. V.</given-names></name></name-alternatives><email xlink:type="simple">oleg_kalachik@hotmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ГКБ № 4, отделение трансплантации почки, Минск</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2000</year></pub-date><pub-date pub-type="epub"><day>28</day><month>06</month><year>2025</year></pub-date><volume>2</volume><issue>1-2</issue><fpage>44</fpage><lpage>48</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Калачик О.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Калачик О.В.</copyright-holder><copyright-holder xml:lang="en">Kalatchik O.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephro.ru/jour/article/view/3781">https://journal.nephro.ru/jour/article/view/3781</self-uri><abstract><p>Проведен анализ результатов трансплантации почки в 2-х группах : 1 группа - 16 пациентов, при лечении которых использована 3-х компонентная иммуносупрессивная схема, отличительной особенностью которой было назначение высоких доз циклоспорина А; 2 группа - 15 пациентов, у которых в иммуносупрессивный протокол введен 4-й компонент - ингибитор пролактина бромэргон и уменьшена доза циклоспорина А в три раза (с 12 мг/кг/сутки до 4 мг/кг/сутки). Для анализа эффективности иммуносупрессивного протокола использован ряд стандартных клинико-лабораторных параметров, дополненных определением уровня фактора некроза опухолей альфа (ФНО-альфа) и VIII фактора свертывания крови (фактора Виллебранда) как маркеров различных вариантов реакции отторжения почечного трансплантата. Сравнительный анализ показал клиническую и экономическую эффективность 4-компонентной иммуносупрессивной схемы.</p></abstract><trans-abstract xml:lang="en"><p>The results of kidney transplantation in two groups of recipients have been analyzed. The first group: 16 patients were held on the 3-drugs regimen of immunosupression characterized by the high dosage of Cyclosporin A; the second group: 15 patients on the 4-drugs regimen.The fourth component was Bromergon, the prolactin inhibitor. In the second group the dosage of Cy A was three times less (4 mg/ kg/d instead of 12 mg/kg/d). The efficacy of the two said regimens was analyzed using a series of standart clinical and lab parameters and the markers of the transplant rejection: the Tumor Necrosis Factor-alpha (TNF-alpha) and factor VIII of coagulation (Willebrand’s factor). The comparison has shown both clinical and economic effect of the 4-drug regimen of immunosupression.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>бромэргон</kwd><kwd>пролактин</kwd><kwd>иммуносупрессия</kwd><kwd>отторжение</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Hardy J., Beauregard H. and Robert F. In progress in Prolactin Physiology and Pathology. Elsevier North Holland, New York. 1978; 361-370.</mixed-citation><mixed-citation xml:lang="en">Hardy J., Beauregard H. and Robert F. In progress in Prolactin Physiology and Pathology. Elsevier North Holland, New York. 1978; 361-370.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Nady E. and Berczi I. Acta Endocrinology 89, 1978; 530-537, 102, 351-357.</mixed-citation><mixed-citation xml:lang="en">Nady E. and Berczi I. Acta Endocrinology 89, 1978; 530-537, 102, 351-357.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Novonha T.L., Daniel V. et al. Transplantation Proceedings 1990; vol. 22, 4, 1859-1860.</mixed-citation><mixed-citation xml:lang="en">Novonha T.L., Daniel V. et al. Transplantation Proceedings 1990; vol. 22, 4, 1859-1860.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vanson W.J., Brijker F. Transplantation Proceedings 1997; 1,2, 161-162.</mixed-citation><mixed-citation xml:lang="en">Vanson W.J., Brijker F. Transplantation Proceedings 1997; 1,2, 161-162.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Russell D., Martizian L. Prolactin Receptors on Human Lymphocytes and Their Modulation by Cyclosporin. Biochemical and Biophysical Reseach Communications, 1984; vol. 121, 3, 899-906.</mixed-citation><mixed-citation xml:lang="en">Russell D., Martizian L. Prolactin Receptors on Human Lymphocytes and Their Modulation by Cyclosporin. Biochemical and Biophysical Reseach Communications, 1984; vol. 121, 3, 899-906.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
